

# Emily C Ayers

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8975615/publications.pdf>

Version: 2024-02-01

12  
papers

182  
citations

1307594

7  
h-index

1199594

12  
g-index

12  
all docs

12  
docs citations

12  
times ranked

362  
citing authors

#	ARTICLE	IF	CITATIONS
1	Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. <i>Blood</i> , 2022, 139, 413-423.	1.4	50
2	High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US Centers. <i>Blood</i> , 2021, 138, 455-455.	1.4	4
3	Antibody and T-Cell Responses to Covid-19 mRNA Vaccines in Patients with B-Cell Lymphomas and Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2021, 138, 1335-1335.	1.4	2
4	Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. <i>Cancer</i> , 2020, 126, 293-303.	4.1	18
5	Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy. <i>British Journal of Haematology</i> , 2020, 189, 313-317.	2.5	7
6	Real World Outcomes in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Receiving Palliative Intent Therapies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 661-667.	0.4	8
7	Hematopoietic stem cell transplantation for blood cancers in the era of precision medicine and immunotherapy. <i>Cancer</i> , 2020, 126, 1837-1855.	4.1	20
8	Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. <i>Blood Advances</i> , 2020, 4, 253-262.	5.2	29
9	Survival outcomes of diffuse large B-cell lymphoma by association with concurrent or antecedent follicular lymphoma and double hit status. <i>Leukemia and Lymphoma</i> , 2019, 60, 3266-3271.	1.3	4
10	Outcome of Patients with Aggressive B Cell Lymphomas Who Receive Second-Line Salvage Immunochemotherapy Following Treatment Failure of Intensive First-Line Immunochemotherapy. <i>Blood</i> , 2018, 132, 453-453.	1.4	1
11	Richter's Transformation in the Era of Kinase Inhibitor Therapy: A Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 1-6.	0.4	11
12	Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CTL019) in Conjunction with Salvage Autologous Stem Cell Transplantation for Advanced Multiple Myeloma. <i>Blood</i> , 2016, 128, 974-974.	1.4	28